Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate

Molecular Pharmacology

Volumn 69, Issue 4, 2006, Pages 1103-1114

  Uno, Shigeyuki ^b   Dalton, Timothy P ^a   Dragin, Nadine ^a   Curran, Christine P ^a   Derkenne, Sandrine ^a   Miller, Marian L ^a   Shertzer, Howard G ^a   Gonzalez, Frank J ^c   Nebert, Daniel W ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DETOXIFICATION; DNA ADDUCT; ENZYME METABOLISM; GENOTYPE; IMMUNE DEFICIENCY; IMMUNOTOXICITY; KNOCKOUT MOUSE; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMUS ATROPHY;

ADMINISTRATION, ORAL; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BENZO(A)PYRENE; BODY BURDEN; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; DNA PRIMERS; GENOTYPE; IMMUNE SYSTEM; METABOLIC DETOXICATION, DRUG; MICE; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION;

EID: 33645105462     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.021501     Document Type: Article

References (51)

1. Alexandrov K, Cascorbi I, Rojas M, Bouvier G, Kriek E, and Bartsch H (2002) CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 23:1969-1977.
2. Buesen R, Mock M, Seidel A, Jacob J, and Lampen A (2002) Interaction between metabolism and transport of benzo[a]pyrene and its metabolites in enterocytes. Toxicol Appl Pharmacol 183:168-178.
3. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, and Gonzalez FJ (1999) Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 96:1977-1982.
4. Conney AH, Chang RL, Jerina DM, and Wei SJ (1994) Studies on the metabolism of benzo[a]pyrene and dose-dependent differences in the mutagenic profile of its ultimate carcinogenic metabolite. Drug Metab Rev 26:125-163.
5. Dalton TP, Dieter MZ, Matlib RS, Childs N, Shertzer HG, Genter MB, and Nebert DW (2000) Targeted knockout in the Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun 267:184-189.
6. Dey A, Jones JE, and Nebert DW (1999) Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized by in situ hybridization. Biochem Pharmacol 58:525-537.
7. Ellard S, Mohammed Y, Dogra S, Wolfel C, Doehmer J, and Parry JM (1991) Use of genetically engineered V79 Chinese hamster cultures expressing rat liver CYP1A1, 1A2 and 2B1 cDNAs in micronucleus assays. Mutagenesis 6:461-470.
8. Farin FM and Omiecinski CJ (1993) Regiospecific expression of cytochromes P-450 and microsomal epoxide hydrolase in human brain tissue. J Toxicol Environ Health 40:317-335.
9. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (Lond) 401:493-497.
10. Foster JR, Idle JR, Hardwick JP, Bars R, Scott P, and Braganza JM (1993) Induction of drug-metabolizing enzymes in human pancreatic cancer and chronic pancreatitis. J Pathol 169:457-463.
11. Galvan N, Jaskula-Sztul R, MacWilliams PS, Czuprynski CJ, and Jefcoate CR (2003) Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liver. Toxicol Appl Pharmacol 193:84-96.
12. Galvan N, Page TJ, Czuprynski CJ, and Jefcoate CR (2006) Benzo[a]pyrene and 7,12-dimethylbenzo[a]anthracene differentially affect bone marrow cells of the lymphoid and myeloid lineages. Toxicol Appl Pharmacol, in press.
13. Galvan N, Teske DE, Zhou G, Moorthy B, MacWilliams PS, Czuprynski CJ, and Jefcoate CR (2005) Induction of CYP1A1 and CYP1B1 in liver and lung by benzo[a]pyrene and 7,12-dimethylbenzo[a]anthracene do not affect distribution of polycyclic hydrocarbons to target tissue: role of AHR and CYP1B1 in bone marrow cytotoxicity. Toxicol Appl Pharmacol 202:244-257.
14. Garcia-Falcon MS, Gonzalez-Amigo S, Lage-Yusty MA, Lopez de Alda Villaizan MJ, and Simal-Lozano J (1996) Determination of benzo[a]pyrene in lipid-soluble liquid smoke (LSLS) by HPLC-FL. Food Addit Contam 13:863-870.
15. Guengerich FP, Chun YJ, Kim D, Gillam EM, and Shimada T (2003) Cytochrome P450 1B1: a target for inhibition in anti-carcinogenesis strategies. Mutat Res 523-524:173-182.
16. Heidel SM, Czuprynski CJ, and Jefcoate CR (1998) Bone marrow stromal cells constitutively express high levels of cytochrome P450 1B1 that metabolize 7,12-dimethylbenzo[a]anthracene. Mol Pharmacol 54:1000-1006.
17. Hem A, Smith AJ, and Solberg P (1998) Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink. Lab Anim 32:364-368.
18. Hundeiker C, Pineau T, Cassar G, Betensky RA, Gleichmann E, and Esser C (1999) Thymocyte development in Ah-receptor-deficient mice is refractory to TCDD-inducible changes. Int J Immunopharmacol 21:841-859.
19. Kim HS, Kwack SJ, and Lee BM (2000) Lipid peroxidation, antioxidant enzymes and benzo[a]pyrene-quinones in the blood of rats treated with benzo[a]pyrene. Chem Biol Interact 127:139-150.
20. Kimura S, Kozak CA, and Gonzalez FJ (1989) Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping and induction by 3-methylcholanthrene. Biochemistry 28:3798-3803.
21. Knize MG, Salmon CP, Pais P, and Felton JS (1999) Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Advanc Exp Med Biol 459:179-193.
22. Laiosa MD, Wyman A, Murante FG, Fiore NC, Staples JE, Gasiewicz TA, and Silverstone AE (2003) Cell proliferation arrest within intrathymic lymphocyte progenitor cells causes thymic atrophy mediated by the aryl hydrocarbon receptor. J Immunol 171:4582-4591.
23. -/- null mutant mice develop normally, but show deficient drug metabolism. Proc Natl Acad Sci USA 93:1671-1676.
24. -/- null mutant mice. Biochem Pharmacol 54:1127-1131.
25. Marnett LJ, Panthananickal A, and Reed GA (1982) Metabolic activation of 7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene during prostaglandin biosynthesis. Drug Metab Rev 13:235-247.
26. Meehan RR, Speed RM, Gosden JR, Rout D, Hutton JJ, Taylor BA, Hilkens J, Kroezen V, Hilgers J, Adesnik M, et al. (1998) Chromosomal organization of the cytochrome P450-2C gene family in the mouse: a locus associated with constitutive aryl hydrocarbon hydroxylase. Proc Natl Acad Sci USA 84:2662-2666.
27. Miller KP and Ramos KS (2001) Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons. Drug Metab Rev 33:1-35.
28. Nebert DW (1989) The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. Crit Rev Toxicol 20:153-174.
29. Nebert DW, Dalton TP, Okey AB, and Gonzalez FJ (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279:23847-23850.
30. Nebert DW, Dalton TP, Stuart GW, and Carvan MJ III (2000a) "Gene-swap knockin" cassette in mice to study allelic differences in human genes. Ann NY Acad Sci 919:148-170.
31. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, and Dalton TP (2000b) Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control and apoptosis. Biochem Pharmacol 59:65-85.
32. Nohara K, Pan X, Tsukumo S, Hida A, Ito T, Nagai H, Inouye K, Motohashi H, Yamamoto M, Fujii-Kuriyama Y, et al. (2005) Constitutively active aryl hydrocarbon receptor expressed specifically in T-lineage cells causes thymus involution and suppresses the immunization-induced increase in splenocytes. J Immunol 174:2770-2777.
33. Pelkonen O and Nebert DW (1982) Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev 34:189-222.
34. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, and Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435-7451.
35. Puga A, Maier A, and Medvedovic M (2000) The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem Pharmacol 60:1129-1142.
36. Rivera SP, Saarikoski ST, and Hankinson O (2002) Identification of a novel dioxin-inducible cytochrome P450. Mol Pharmacol 61:255-259.
37. Robinson JR, Felton JS, Levitt RC, Thorgeirsson SS, and Nebert DW (1975) Relationship between "aromatic hydrocarbon responsiveness" and the survival times in mice treated with various drugs and environmental compounds. Mol Pharmacol 11:850-865.
38. Ryu DY, Levi PE, Fernandez-Salguero P, Gonzalez FJ, and Hodgson E (1996) Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. Mol Pharmacol 50:443-446.
39. Sesardic D, Pasanen M, Pelkonen O, and Boobis AR (1990) Differential expression and regulation of members of the cytochrome P450 IA gene subfamily in human tissues. Carcinogenesis 11:1183-1188.
40. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, and Sutter TR (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56:2979-2984.
41. Shimada T, Oda Y, Gillam EM, Guengerich FP, and Inoue K (2001) Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos 29:1176-1182.
42. Staples JE, Murante FG, Fiore NC, Gasiewicz TA, and Silverstone AE (1998) Thymic alterations induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are strictly dependent on aryl hydrocarbon receptor activation in hemopoietic cells. J Immunol 160:3844-3854.
43. Tatemichi M, Nomura S, Ogura T, Sone H, Nagata H, and Esumi H (1999) Mutagenic activation of environmental carcinogens by microsomes of gastric mucosa with intestinal metaplasia. Cancer Res 59:3893-3898.
44. Tomita S, Jiang HB, Ueno T, Takagi S, Tohi K, Maekawa S, Miyatake A, Furukawa A, Gonzalez FJ, Takeda J, et al. (2003) T cell-specific disruption of aryl hydrocarbon receptor nuclear translocator (Arnt) gene causes resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced thymic involution. J Immunol 171:4113-4120.
45. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, and Nebert DW (2004a) Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 65:1225-1237.
46. -/- knockout mice having increased hepatic benzo[a]pyrene-DNA adduct levels. Biochem Biophys Res Commun 289:1049-1056.
47. -/- male mice: protection against high-dose TCDD-induced lethality and wasting syndrome and resistance to intra-hepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol 196:410-421.
48. Walker NJ, Gastel JA, Costa LT, Clark GC, Lucier GW, and Sutter TR (1995) Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals. Carcinogenesis 16:1319-1327.
49. Wei C, Caccavale RJ, Kehoe JJ, Thomas PE, and Iba MM (2001) CYP1A2 is expressed along with CYP1A1 in the human lung. Cancer Lett 171:113-120.
50. Winer J, Jung CK, Shackel I, and Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41-49.
51. Zhang QY, Dunbar D, and Kaminsky LS (2003) Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31:1346-1351.